SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aarti Pharmalabs informs about disclosure

17 Dec 2024 Evaluate
Aarti Pharmalabs has informed that the Company has received from Constituted Attorney(ies) representing the Persons prescribed in Schedule I of Annexure to the agreement an intimation under Regulation 30A(1) of the Listing Regulations read with Clause 5A, Para A, Part A, Schedule III of the Listing Regulations on December 16, 2024. The details as required pursuant to Regulation 30 read with Schedule Ill of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 are also mentioned in the attached agreement. The below information will also be available on the website of the Company at www.aartipharmalabs.com.

The above information is a part of company’s filings submitted to BSE.

Aarti Pharmalabs Share Price

688.15 -4.80 (-0.69%)
23-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1679.85
Dr. Reddys Lab 1333.05
Cipla 1305.85
Zydus Lifesciences 947.10
Lupin 2340.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×